Showing results (661-670 of 5,837) with videos related to

Sort By:
Pageof 584
Drug Design, Development and Therapy|January 11, 2020
Cytokine and Chemokine Profile Changes in Patients After Intravitreal Conbercept Injection for Diabetic Macular EdemaQingquan Wei, Zhongqi Wan, Yongcheng Hu, et al.
Drug Design, Development and Therapy|January 11, 2020
Inhibition of Disruptor of Telomeric Silencing 1-Like Alleviated Renal Ischemia and Reperfusion Injury-Induced Fibrosis by Blocking PI3K/AKT-Mediated Oxidative StressChuan Yang, Zhiyuan Chen, Hua Yu, et al.
Drug Design, Development and Therapy|January 11, 2020
An Efficient, Lung-Targeted, Drug-Delivery System To Treat Asthma Via MicroparticlesNagaraja SreeHarsha, Katharigatta N Venugopala, Anroop B Nair, et al.
Drug Design, Development and Therapy|January 11, 2020
Developmental Pharmacogenetics of SLCO2B1 on Montelukast Pharmacokinetics in Chinese ChildrenQian Li, Kai Wang, Hai-Yan Shi, et al.
Drug Design, Development and Therapy|July 28, 2015
Bacteriophage-based therapy in cystic fibrosis-associated Pseudomonas aeruginosa infections: rationale and current statusSami Hraiech, Fabienne Brégeon, Jean-Marc Rolain
Drug Design, Development and Therapy|January 2, 2015
Temsirolimus for patients with metastatic renal cell carcinoma: outcomes in patients receiving temsirolimus within a compassionate use program in a tertiary referral centerMehran Afshar, Jennifer Pascoe, Sue Whitmarsh, et al.
Drug Design, Development and Therapy|January 2, 2015
Analysis of malignancies in patients after heart transplantation with subsequent immunosuppressive therapyRasmus Rivinius, Matthias Helmschrott, Arjang Ruhparwar, et al.
Drug Design, Development and Therapy|January 2, 2015
Pharmacological approaches to improving cognitive function in Down syndrome: current status and considerationsKatheleen J Gardiner
Drug Design, Development and Therapy|December 12, 2018
Arsenic sulfide amplifies JQ1 toxicity via mitochondrial pathway in gastric and colon cancer cellsZhen Tan, Xiuli Zhang, Ting Kang, et al.
Drug Design, Development and Therapy|January 23, 2019
Hyperprogression after anti-programmed cell death ligand-1 therapy in a patient with recurrent metastatic urothelial bladder carcinoma following first-line cisplatin-based chemotherapy: a case reportShiyu Mao, Junfeng Zhang, Yadong Guo, et al.
Pageof 584